Jungsil Ro

20.3k citations

189 papers · 13.3k indexed · 5 hit papers · h-index 52

Impact in

Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
Cancer Research top 0.2%
- Breast Cancer Treatment Studies

Papers in

Cancer Research 66
- Breast Cancer Treatment Studies 47
Oncology 117
- HER2/EGFR in Cancer Research 57
- Cancer Treatment and Pharmacology 51

Co-authors: Keun Seok Lee Hiroji Iwata Sunil Verma Nadia Harbeck Cynthia Huang Bartlett Massimo Cristofanilli Sung‐Bae Kim Nicholas C. Turner
Journals: Journal of Clinical Oncology (22 papers)Cancer Research (13 papers)Breast Cancer Research and Treatment (12 papers)Cancer Research and Treatment (10 papers)Annals of Oncology (9 papers)
Partner nations: South Korea United States Canada

In The Last Decade

Jungsil Ro

188 papers receiving 13.1k citations

Hit Papers

5 papers align trajectories log scale

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer 2018 · 777 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 New England Journal of Medicine
2016 The Lancet Oncology
2015 New England Journal of Medicine
2015 New England Journal of Medicine
2013 The Lancet Oncology

Peers

Countries citing papers authored by Jungsil Ro

Since Specialization

Citations

This map shows the geographic impact of Jungsil Ro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jungsil Ro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jungsil Ro more than expected).

Fields of papers citing papers by Jungsil Ro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jungsil Ro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jungsil Ro. The network helps show where Jungsil Ro may publish in the future.

Co-authors

The 25 scholars most cited alongside Jungsil Ro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jungsil Ro Line = papers co-authored together Jungsil Ro links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer PLoS ONE ·Sung Hoon Sim, Chang‐Dae Bae, F. Conte, V. O. Obanawu, AP Jadhav, A. Napp, Kyung‐Tae Kim, Shimomura, Han‐Seong Kim, Tae Hyun Um, In Hae Park, Keun Seok Lee, So‐Youn Jung, Rajanala Vara Lakshmi, Han‐Sung Kang, Kyu Eun Lee, Mi‐Kyung Kim, Kyeong‐Man Hong, Jungsil Ro	2017	17
2	Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results The Oncologist ·Sibylle Loibl, Nicholas C. Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock‐Ah Im, Norikazu Masuda, Sherene Loi, Fabrice André, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitch Dowsett	2017	99
3	A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients Annals of Oncology ·Toshiaki Saeki, Hirofumi Mukai, Jungsil Ro, 李允渙, Yasuhiro Fujiwara, Shigenori E. Nagai, Jo Flottorp Ness, Junichiro Watanabe, Shoichiro Ohtani, S.B. Kim, Katsumasa Kuroi, Koichiro Tsugawa, Yutaka Tokuda, Hiroji Iwata, Y.H. Park, Youngsen Yang, Yoshihiro Nambu	2017	7
4	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer Clinical Cancer Research ·José Baselga, Gail D. Lewis Phillips, Sunil Verma, Jungsil Ro, Jens Huober, Alice E. Guardino, Meghna Samant, Steve Olsen, Sanne Lysbet de Haas, Mark D. Pegram	2016	150
5	An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer Cancer Research and Treatment ·In Hae Park, Joohyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyun Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Song, Jae Hong Seo, Hun Mo Ryoo, O. Vitells, So Young Yoon, Chul Soo Kim, S. Amponsem, Sang Yong Kim, SameerV Baliga, Jungsil Ro	2016	90
6	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial The Lancet Oncology ·Nadia Harbeck, Chiun‐Sheng Huang, Sara A. Hurvitz, Dah‐Cherng Yeh, Zhimin Shao, Seock‐Ah Im, Kyung Hae Jung, Kunwei Shen, Jungsil Ro, Jacek Jassem, Qingyuan Zhang, Young‐Hyuck Im, Marek Z. Wojtukiewicz, Qiang Sun, Shin‐Cheh Chen, Rainer-Georg Goeldner, Martina Uttenreuther‐Fischer, Binghe Xu, Martine Piccart	2016	105
7	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial The Lancet Oncology ·Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, María Koehler, Dennis J. Slamon Hit paper breakdown →	2016	1247
8	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation European Journal of Cancer ·David Miles, David Cameron, Igor Bondarenko, Werden in, Juan Carlos Alcedo, R.I. Lopez, Seock‐Ah Im, Jean‐Luc Canon, Yaroslav Shparyk, Denise A. Yardley, Norikazu Masuda, Jungsil Ro, Neelima Denduluri, Stanislas Hubeaux, Cheng S. Quah, Carlos Bais, Joyce O’Shaughnessy	2016	92
9	Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial Annals of Oncology ·Nadia Harbeck, Shrividya Iyer, Nicholas C. Turner, Massimo Cristofanilli, Jungsil Ro, Fabrice André, Sherene Loi, S. Verma, Hiroji Iwata, Helen Bhattacharyya, Kathy Puyana Theall, Cynthia Huang Bartlett, Sibylle Loibl	2016	114
10	Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer Clinical Breast Cancer ·In Hae Park, Sun‐Young Kong, Jae Y. Ro, (unknown), Youngmee Kwon, Joo Hyun Kang, Vladimir Aleksandrovich, So‐Youn Jung, Seeyoun Lee, Keun Seok Lee, Han‐Sung Kang, Eun-Sook Lee, Jungnam Joo, Jungsil Ro	2015	74
11	MicroRNA signature for HER2-positive breast and gastric cancer. PubMed ·Han Sung Kang, Sang‐Geun Jang, Sun Young Kwon, Young Soo Park, Jeffrey E. Green, Hark Kyun Kim, Jungsil Ro	2014	16
12	A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer Cancer Letters ·Seungyoon Nam, Hae Ryung Chang, Hae Rim Jung, Linda McKeane Weseloh, Andrea De Nigris, Régis Grailhe, Haeng Ran Seo, 吴朝轻, Curt Balch, Jinhyuk Lee, Giulia Manco, 雅己山中, Kyung‐Chae Jeong, Garth Powis, Han Liang, Eun Sook Lee, Jungsil Ro, Yon Hui Kim	2014	29
13	Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02 Journal of Clinical Oncology ·Winnie Yeo, Kyung Hae Jung, Seock‐Ah Im, Joohyuk Sohn, Jungsil Ro, Jin Hee Ahn, Sung‐Bae Kim, Byung‐Ho Nam, Do Youn Oh, Sae‐Won Han, Soo Hyun Lee, In Hae Park, Keun Seok Lee, Jee Hyun Kim, Seok Yun Kang, Moon Hee Lee, Hee Sook Park, Jin Seok Ahn, Young‐Hyuck Im	2013	54
14	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer ·Miguel Martín, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, István Láng, Sung‐Bae Kim, Caroline Germa, Jennifer Vermette, Н.В. Мартинович, Kongming Wang, Ahmad Awada	2013	119
15	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study The Lancet Oncology ·Sandra M. Swain, Sung‐Bae Kim, Javier Cortés, Jungsil Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiß, Adam Knott, Emma Clark, Graham Ross, Mark Benyunes, José Baselga Hit paper breakdown →	2013	700
16	Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01 Breast Cancer Research and Treatment ·Seock‐Ah Im, Keun Seok Lee, Jungsil Ro, Eun Sook Lee, Youngmee Kwon, Jin‐Hee Ahn, Jin Seok Ahn, Jee Hyun Kim, Han Sung Kang, Kyung Hwan Shin, Dong‐Young Noh, In-Ae Park, Sung‐Bae Kim, Young Hyuck Im, Sung Whan Ha	2011	9
17	Adipocyte Enhancer-Binding Protein 1 (AEBP1) (a Novel Macrophage Proinflammatory Mediator) Overexpression Promotes and Ablation Attenuates Atherosclerosis in ApoE−/− and LDLR−/− Mice Molecular Medicine ·Oleg Bogachev, Amin F. Majdalawieh, Xuefang Pan, Lei Zhang, Jungsil Ro	2011	29
18	Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer Annals of Oncology ·Zhan-Bo Fang, Jungsil Ro, Cristian Velasco-Merino, Byung‐Ho Nam, Youngmee Kwon, Sadie M. Miller	2008	101
19	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer Breast Cancer Research and Treatment ·Keun Seok Lee, Hyun Cheol Chung, Seock Ah Im, Winnie Yeo, Chul Soo Kim, Sung‐Bae Kim, Sun Young Rha, Min Young Lee, Jungsil Ro	2007	402
20	Characterization of three transcriptional repressor sites within the 3′ untranslated region of the rat serine protease inhibitor 2.3 gene European Journal of Biochemistry ·Conception Paul, Indrawati Purbaningsih, Jungsil Ro, Alphonse Le Cam	1998	3

About Jungsil Ro

Jungsil Ro is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Molecular Biology, having authored 189 papers that have together received 13.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (57 papers), Cancer Treatment and Pharmacology (51 papers), Breast Cancer Treatment Studies (47 papers), Advanced Breast Cancer Therapies (31 papers), Breast Lesions and Carcinomas (19 papers), Peroxisome Proliferator-Activated Receptors (15 papers), Estrogen and related hormone effects (13 papers) and Brain Metastases and Treatment (9 papers). The work is most often cited by research in Oncology (7.9k citations), Cancer Research (3.6k citations), Pulmonary and Respiratory Medicine (5.3k citations), Genetics (1.3k citations) and Radiology, Nuclear Medicine and Imaging (1.4k citations). Jungsil Ro has collaborated with scholars based in South Korea, United States and Canada. Frequent co-authors include Keun Seok Lee, Hiroji Iwata, Sunil Verma, Nadia Harbeck, Cynthia Huang Bartlett, Massimo Cristofanilli, Sung‐Bae Kim, Nicholas C. Turner, Sherene Loi and Amin F. Majdalawieh. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Cancer Research and Treatment and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact